NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in Hepatitis C virus genotype 4 infection

Journal of Infectious Diseases

Volumn 213, Issue 2, 2016, Pages 206-215

  Zhou, Nannan ^a   Hernandez, Dennis ^a   Ueland, Joseph ^a   Yang, Xiaoyan ^a   Yu, Fei ^a   Sims, Karen ^a   Yin, Philip D ^a   McPhee, Fiona ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

daclatasvir; HCV; NS5A; polymorphism; resistance

Indexed keywords

ASUNAPREVIR; BECLABUVIR; DACLATASVIR; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON; RIBAVIRIN; BMS-790052; IMIDAZOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DOSE RESPONSE; GENETIC POLYMORPHISM; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; OPEN STUDY; PHYLOGENY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPLICON; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; AMINO ACID SUBSTITUTION; CLASSIFICATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HEALTH; HEPACIVIRUS; METABOLISM; PHYSIOLOGY; VIROLOGY;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; GENE EXPRESSION REGULATION, VIRAL; GENOTYPE; GLOBAL HEALTH; HEPACIVIRUS; HEPATITIS C; HUMANS; IMIDAZOLES; PHYLOGENY; POLYMORPHISM, GENETIC; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84959866569     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv379     Document Type: Article

References (45)

1. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource. Hepatology 2014; 59:318-27.
2. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don t yet know. Hepatology 2008; 47:1371-83.
3. Karoney MJ, Siika AM. Hepatitis C virus (HCV) infection in Africa: a review. Pan Afr Med J 2013; 14:44.
4. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61:77-87.
5. Lyra AC, Ramrakhiani S, Bacon BR, Di Bisceglie AM. Infection with hepatitis C virus genotype 4 in the United States. J Clin Gastroenterol 2004; 38:68-71.
6. Kershenobich D, Razavi HA, Sanchez-Avila JF, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int 2011; 31(suppl 2):18-29.
7. Al Ashgar HI, Khan MQ, Al-Ahdal M, et al. Hepatitis C genotype 4: genotypic diversity, epidemiological profile, and clinical relevance of subtypes in Saudi Arabia. Saudi J Gastroenterol 2013; 19:28-33.
8. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014; 349:g3308.
9. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87.
10. Moreno C, Hezode C, Marcellin P, et al. Efficacy and safety of simeprevir with pegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J Hepatol 2015; 62:1047-55.
11. Hezode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2015; 64:948-56.
12. Bronowicki JP, Ratziu V, Gadano A, et al. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. J Hepatol 2014; 61:1220-7.
13. Lawitz E, Rodriguez-Torres M, Nguyen T, et al. A phase II study of samatasvir (IDX719) in combination with simeprevir and ribavirin in treatment-naïve HCV-infected subjects with genotypes 1b and 4 (HELIX-1 study) [abstract]. J Hepatol 2014; 60:S495-6.
14. Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-Experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015; 385:2502-9.
15. Hassanein T, Sims KD, Bennett M, et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol 2015; 62:1204-6.
16. Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015; 62:1040-6.
17. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebocontrolled trial. Lancet 2014; 384:403-13.
18. Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: in vitro and in vivo correlations. Hepatology 2011; 54:1924-35.
19. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-Acting antiviral agents. Antiviral Res 2014; 108C:181-91.
20. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014; 146:1176-92.
21. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.
22. Pol S. Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virological data, treatment rationale and clinical trials. Clin Invest 2013; 3:191-207.
23. Hezode C, Alric L, Brown A, et al. Daclatasvir in combination with peginterferon alfa-2a and ribavirin for treatment-naive patients with HCV genotype 4 infection: phase 3 COMMAND-4 results [abstract 819]. Presented at: IDWeek 2014, Philadelphia, PA, 8-12 October, 2014.
24. Jensen D, Sherman KE, Hezode C, et al. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol 2015; 63:30-7.
25. Combet C, Garnier N, Charavay C, et al. euHCVdb: the European hepatitis C virus database. Nucleic Acids Res 2007; 35:D363-6.
26. Gottwein JM, Scheel TK, Callendret B, et al. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol 2010; 84:5277-93.
27. McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 2013; 58:902-11.
28. Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother 2013; 57:611-3.
29. Fridell RA, Qiu D,Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010; 54:3641-50.
30. Kato T, Date T, Miyamoto M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 2003; 125: 1808-17.
31. Wang C, Jia L, Huang H, et al. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother 2012; 56:1588-90.
32. Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384:1597-605.
33. Lok A, Gardiner D, Hézode C, et al. Randomized trial of daclatasvir and asunaprevir with or without peginterferon/ribavirin for hepatitis C virus genotype 1 null responders. J Hepatol 2014; 60:490-9.
34. Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferonand ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014; 146:420-9.
35. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59:2083-91.
36. Nettles RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011; 54:1956-65.
37. Hernandez D, Ueland J, Yu F, et al. Characterization of HCV genotype 1 NS5A resistance variants from the phase 2b COMMAND-1 study: daclatasvir plus peginterferon-Alfa/ribavirin in treatment-naive patients [abstract]. Hepatology 2012; 56(4 suppl):580-1A.
38. Link JO, Taylor JG, Xu L, et al. Discovery of ledipasvir (GS-5885): a potent, oncedaily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem 2014; 57:2033-46.
39. McPhee F, Hernandez D, Zhou N, et al. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir Ther 2014; 19:479-90.
40. Sun JH, O Boyle II DR, Zhang Y, et al. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052. Hepatology 2012; 55:1692-9.
41. de Bruijne J, Schinkel J, Prins M, et al. Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles. J Clin Microbiol 2009; 47:3832-8.
42. Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14:460-7.
43. Suzuki F, Sezaki H, Akuta N, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012; 54: 352-4.
44. Peng B, Yu M, Xu S, et al. Development of robust hepatitis C virus genotype 4 subgenomic replicons. Gastroenterology 2013; 144:59-61.
45. Saeed M, Scheel TK, Gottwein JM, et al. Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob Agents Chemother 2012; 56:5365-73.